Drug Profile
TRPH 222
Alternative Names: CAT-02-106; CD22 ADC - Bristol Myers Squibb; CD22 antibody drug conjugate - Bristol Myers Squibb/Triphase Accelerator Corporation; CD22-4AP; TRPH-222Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Catalent Pharma Solutions
- Developer Triphase Accelerator Corporation
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in Canada (IV)
- 28 Feb 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in USA (IV)
- 09 Jun 2022 Efficacy and adverse events data from a phase I trial in B-cell lymphoma presented at the 27th Congress of the European Haematology Association (EHA-2022)